NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Forecast & News

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($2.17) by $0.25. The biopharmaceutical company earned $70.06 million during the quarter, compared to analysts' expectations of $57.14 million. Alnylam Pharmaceuticals had a negative return on equity of 52.88% and a negative net margin of 485.73%. The firm's quarterly revenue was up 3284.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.56) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Alnylam Pharmaceuticals.

17 brokers have issued 12-month price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $62.00 to $190.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $121.59 in the next twelve months. This suggests a possible upside of 4.1% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.

Media coverage about ALNY stock has been trending extremely negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 4,420,000 shares, a decline of 10.5% from the December 15th total of 4,940,000 shares. Based on an average trading volume of 694,700 shares, the short-interest ratio is currently 6.4 days. Approximately 4.0% of the company's stock are sold short. View Alnylam Pharmaceuticals' Current Options Chain.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), NXP Semiconductors (NXPI), Gilead Sciences (GILD), Mylan (MYL), Netflix (NFLX), Opko Health (OPK) and Micron Technology (MU).

Alnylam Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.14%), Coronation Fund Managers Ltd. (0.09%), Rhenman & Partners Asset Management AB (0.05%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), DNB Asset Management AS (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Paul Schimmel, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Coronation Fund Managers Ltd., Nisa Investment Advisors LLC, Rhenman & Partners Asset Management AB, Zeke Capital Advisors LLC, IFM Investors Pty Ltd and Gateway Investment Advisers LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Barry E Greene, John Maraganore, Marsha Fanucci, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.

ALNY stock was bought by a variety of institutional investors in the last quarter, including Polianta Ltd, Zurcher Kantonalbank Zurich Cantonalbank , Tocqueville Asset Management L.P., IBM Retirement Fund, DNB Asset Management AS, Exchange Traded Concepts LLC and Huntington National Bank. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALNY stock can currently be purchased for approximately $116.83.

Alnylam Pharmaceuticals has a market capitalization of $13.02 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals.

The official website for Alnylam Pharmaceuticals is http://www.alnylam.com/.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]